Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas

Table 3 Toxicity profile of lenalidomide in clinical trials for T-cell lymphomas

Toxicity/Adverse event	Ishida et al[44]	Querfeld et al[52]	Morschhauser et al[51]	Toumishey et al[57]
Hematological toxicity
Anemia total	54%	41%	NR	26%
Anemia grade 3-4	19.2%	/	4%	11%
Leukopenia total	50%	22%	NR	NR
Leukopenia grade 3-4	38.5%	3%	4%	NR
Neutropenia total	73%	NR	NR	18%
Neutropenia grade 3-4	65.4%	NR	15%	16%
Thrombocytopenia total	77%	NR	NR	26%
Thrombocytopenia grade 3-4	23.1%	NR	20%	5%
Hypoalbuminemia	35%	28%	NR	NR
Grade 3-4	/	/	NR	NR
Constipation	31%	34%1	17%	44%
Grade 3-4	/	/	NR	3%
Nausea	23.1%	13%	NR	28%
Grade 3-4	3.8%	/	NR	/
Vomiting	23.1%	NR	NR	10%
Grade 3-4	/	NR	NR	/
Skin rash	23.1%	25%	NR	38%
Grade 3-4	7.6%	/	9%	11%
Fatigue	15.4%	59%	NR	56%
Grade 3-4	3.8%	22%	NR	11%
Diarrhea	NR	NR	NR	31%
Grade 3-4	NR	NR	NR	8%
Pain	NR	34%	NR	64%
Grade 3-4	NR	/	NR	21%
Infection	19.2%	34%	NR	26%
Grade 3-4	10.4%	9%	15%	5%
Neuropathy	NR	19%	NR	NR
Grade 3-4	NR	/	NR	NR
Lower leg edema	NR	47%	NR	28%
Grade 3-4	NR	/	NR	3%
Anorexia	NR	16%	NR	28%
Grade 3-4	NR	/	NR	5%
Respiratory disorders	10.4%	NR	NR	26%
Grade 3-4	7.6%	NR	13%	13%
Pulmonary embolism	NR	NR	NR	10%
Grade 3-4	NR	NR	NR	8%
Tumor flare reaction	NR	28%	14%	NR
Grade 3-4	NR	NR	4%	NR

¹Considered together with diarrhea; Gastrointestinal disorders. NR: Not reported.